PATADAY TWICE DAILY RELIEF Drug Patent Profile
✉ Email this page to a colleague
When do Pataday Twice Daily Relief patents expire, and what generic alternatives are available?
Pataday Twice Daily Relief is a drug marketed by Alcon Labs Inc and is included in one NDA.
The generic ingredient in PATADAY TWICE DAILY RELIEF is olopatadine hydrochloride. There are seventeen drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the olopatadine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Pataday Twice Daily Relief
A generic version of PATADAY TWICE DAILY RELIEF was approved as olopatadine hydrochloride by APOTEX INC on October 8th, 2014.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PATADAY TWICE DAILY RELIEF?
- What are the global sales for PATADAY TWICE DAILY RELIEF?
- What is Average Wholesale Price for PATADAY TWICE DAILY RELIEF?
Summary for PATADAY TWICE DAILY RELIEF
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 93 |
Clinical Trials: | 7 |
Patent Applications: | 1,088 |
Formulation / Manufacturing: | see details |
DailyMed Link: | PATADAY TWICE DAILY RELIEF at DailyMed |
![PATADAY TWICE DAILY RELIEF drug patent expirations Drug patent expirations by year for PATADAY TWICE DAILY RELIEF](/p/graph/s/t/PATADAY_TWICE_DAILY_RELIEF-patent-expirations.png)
Recent Clinical Trials for PATADAY TWICE DAILY RELIEF
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Andover Research Eye Institute | Phase 4 |
Allergan | Phase 4 |
McCabe Vision Center | N/A |
Pharmacology for PATADAY TWICE DAILY RELIEF
Drug Class | Histamine-1 Receptor Antagonist Histamine-1 Receptor Inhibitor Mast Cell Stabilizer |
Mechanism of Action | Histamine H1 Receptor Antagonists |
Physiological Effect | Decreased Histamine Release |
Paragraph IV (Patent) Challenges for PATADAY TWICE DAILY RELIEF
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
PATADAY TWICE DAILY RELIEF | Ophthalmic Solution | olopatadine hydrochloride | 0.1% | 020688 | 1 | 2006-07-17 |
US Patents and Regulatory Information for PATADAY TWICE DAILY RELIEF
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alcon Labs Inc | PATADAY TWICE DAILY RELIEF | olopatadine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 020688-001 | Dec 18, 1996 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PATADAY TWICE DAILY RELIEF
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Alcon Labs Inc | PATADAY TWICE DAILY RELIEF | olopatadine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 020688-001 | Dec 18, 1996 | ⤷ Sign Up | ⤷ Sign Up |
Alcon Labs Inc | PATADAY TWICE DAILY RELIEF | olopatadine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 020688-001 | Dec 18, 1996 | ⤷ Sign Up | ⤷ Sign Up |
Alcon Labs Inc | PATADAY TWICE DAILY RELIEF | olopatadine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 020688-001 | Dec 18, 1996 | ⤷ Sign Up | ⤷ Sign Up |
Alcon Labs Inc | PATADAY TWICE DAILY RELIEF | olopatadine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 020688-001 | Dec 18, 1996 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for PATADAY TWICE DAILY RELIEF
See the table below for patents covering PATADAY TWICE DAILY RELIEF around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Austria | 51867 | ⤷ Sign Up | |
Japan | S6310784 | DIBENZ(B,E)OXEPIN DERIVATIVE, ANTIALLERGIC AGENT AND ANTI-INFLAMMATORY AGENT | ⤷ Sign Up |
Singapore | 38393 | ⤷ Sign Up | |
Norway | 311637 | ⤷ Sign Up | |
European Patent Office | 0316022 | Composés tricycliques. (Tricyclic compounds.) | ⤷ Sign Up |
Mexico | 9701013 | FORMULACIONES OFTALMICOS TOPICAS QUE CONTIENEN DERIVADOR DE DOXEPINA PARA TRATAMIENTO DE ENFERMEDADES OCULARES ALERGICAS. (TOPICAL OPHTHALMIC FORMULATIONS CONTAINING DOXEPIN DERIVATIVES FOR TREATING ALLERGIC EYE DISEASES.) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for PATADAY TWICE DAILY RELIEF
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0799044 | SPC029/2002 | Ireland | ⤷ Sign Up | SPC029/2002: 20040930, EXPIRES: 20170516 |
3043773 | 21C1057 | France | ⤷ Sign Up | PRODUCT NAME: MOMETASONE OU L'UN DE SES SELS AVEC OLOPATADINE OU L'UN DE SES SELS; NAT. REGISTRATION NO/DATE: NL52121 20211026; FIRST REGISTRATION: AT - 140638 20210426 |
3043773 | 301154 | Netherlands | ⤷ Sign Up | PRODUCT NAME: MOMETASON OF EEN ZOUT DAARVAN EN OLOPATADINE OF EEN ZOUT DAARVAN; NATIONAL REGISTRATION NO/DATE: RVG 126186 20211014; FIRST REGISTRATION: AT 140638 20210426 |
3043773 | 2022C/520 | Belgium | ⤷ Sign Up | PRODUCT NAME: MOMETASONE OF EEN ZOUT HIERVAN EN OLOPATADINE OF EEN ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: BE595626 20220203 |
0799044 | 02C0040 | France | ⤷ Sign Up | PRODUCT NAME: OLOPATADINE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/02/217/001 20020517 |
0799044 | SPC/GB02/041 | United Kingdom | ⤷ Sign Up | SPC/GB02/041: 20021018 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |